Navigation Links
ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Date:3/6/2008

- Update on Clinical Developments

MONTREAL, March 6 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announces favorable top-line findings from the third cohort in its Phase II trial with PBI-1402 in patients with chemotherapy-induced anemia ("CIA"). Analysis of the compiled data from a total of 18 patients showed an overall statistically significant increase of the mean hematocrit values at weeks 4, 6 and 8, and of the hemoglobin values at week 8. At week 8, p values were 0.02 for hematocrit and hemoglobin. More detailed results from the study have been submitted to the European Hematology Association for presentation at their June 2008 meeting in Copenhagen.

"These results are very encouraging and continue to demonstrate the efficacy and safety profile of PBI-1402, a non-EPO (erythropoietin) treatment for CIA," states Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc. "We are excited about the prospects for PBI-1402 for the treatment of anemia in oncology since, unlike EPO, PBI-1402 demonstrated some anticancer activity in animal models. We look forward to sharing more detailed clinical trial results."

Other PBI-1402 development highlights include the extension of the enrollment for the PBI-1402 CIA trial to include an additional 12 patients receiving the lowest trial dose. Data from these additional patients are expected by June 2008.

In addition, a new Phase II study in patients with anemia resulting from chronic kidney disease has been scheduled. This multi-center study will be placebo controlled and will examine the effect of PBI-1402 on anemia, as well as several other clinical parameters. Conclusive results obtained recently in animal models have confirmed the erythropoiesis activity of PBI-1402 even when there is little or no endogenous EPO produced by the kidney.

About PBI-1402

PBI-1402 is an orally active compound being develo
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
2. ProMetic provides business update - Over $35 million worth of business secured in January
3. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
4. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
5. VaxGen Reports Financial Update
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
8. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
9. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... has initiated coverage of Alliqua, Inc. (OTCQB: ALQA). ... manufacturing, and marketing proprietary products to serve the ... http://equitiesiq.com/reports/alliqua/ , In late 2012, Alliqua was ... which launched the company’s new strategy to become ...
(Date:1/14/2014)... 2014 In recent years, growing ... and methods in product development and promotion has ... the industry. This mistrust, fueled by concerns about ... been further fed by reports of spectacular fines ... activities, allegations of industry suppression of negative clinical ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ... said Dr. Andrew Brown, SPIE Senior Director for Global ...
(Date:1/14/2014)... 2014 BioMedomics, Inc. , a ... POC diagnostic platforms and novel disease specific POC tests, ... round of financing netting a total of $690,000. The ... outside equity capital in the company. This group of ... in diagnostics companies and includes Tom Roberg who was ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... the Trudeau Institute may help to explain why live ... protection. The research is published in this month,s ... entitled "Live attenuated influenza vaccine (LAIV) impacts innate and ... scientist Dr. Laura Haynes and her colleagues. "Our ...
... ARBOR, Mich.---A delicate balance of atomic forces can be ... size---an attribute that,s important for many nanotech applications but ... The same type of forces are at work ... inorganic supercluster structures in this research are in many ...
... ST. LOUIS, Aug. 23, 2011 Bunge North America, ... BG ), issued the following statement which can be ... "Bunge North America is aware from press ... prior conversations with Syngenta, we are surprised and disappointed that ...
Cached Biology Technology:Trudeau Institute announces a discovery in how FluMist elicits protection 2Engineers discover nanoscale balancing act that mirrors forces at work in living systems 2Bunge Responds to Syngenta Suit 2
(Date:4/16/2014)... up, and you cannot lift your upper eyelid. You walk ... eyes look straight when they are rolled down in the ... allow people a normal position of their head. In order ... this happens. , In a paper published in the April ... of Iowa researchers Bernd Fritzsch and Jeremy Duncan and their ...
(Date:4/16/2014)... Adam Arkin, director of the Physical Biosciences Division ... a biologist who is recognized as a leading ... networks and populations and their application to systems ... six recipients of the 2013 Ernest Orlando Lawrence ... E.O. Lawrence Award, the Department of Energy (DOE),s ...
(Date:4/16/2014)... Aktories and Dr. Panagiotis Papatheodorou from the Institute of ... of Freiburg have discovered the receptor responsible for smuggling ... into the cell. The TpeL toxin, which is formed ... gas gangrene and food poisoning. It is very similar ... the genus Clostridium . The toxins bind to ...
Breaking Biology News(10 mins):Researchers track down cause of eye mobility disorder 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 3Gate for bacterial toxins found 2
... give the Anne McLaren Memorial Lecture at the UK National Stem ... to screening for drugs that target stem cells. To begin with, ... for new drugs to promote wound healing and aid the use ... can also be applied to a wide range of stem cells, ...
... food source, with a global harvest now at 110 million ... But epidemics of infectious disease threaten this vital industry, including ... Perhaps even more worrisome: these infections can spread to wild ... escaping from them. Heart and skeletal muscle ...
... nanotechnology in the field of drug delivery has attracted ... holds great promise for the development of targeted, localized ... are affected. Such targeted-therapy methods would ... anticancer drugs are distributed throughout the body, attacking healthy ...
Cached Biology News:Top professor will report new way to discover drugs that aid regenerative medicine 2New virus may pose risk to wild salmon 2Researchers use nanoparticles to shrink tumors in mice 2Researchers use nanoparticles to shrink tumors in mice 3